InnoCare Pharma Limited (OTCMKTS:INCPF) Short Interest Down 50.9% in May

InnoCare Pharma Limited (OTCMKTS:INCPF) was the recipient of a significant decline in short interest during the month of May. As of May 15th, there was short interest totaling 2,773,329 shares, a decline of 50.9% from the April 30th total of 5,643,832 shares. Based on an average daily volume of 0 shares, the days-to-cover ratio is currently ∞ days.

InnoCare Pharma Price Performance

OTCMKTS:INCPF remained flat at $1.55 on Monday. The firm’s fifty day moving average is $1.55 and its 200-day moving average is $1.83. InnoCare Pharma has a 1 year low of $1.55 and a 1 year high of $2.31.

Analyst Ratings Changes

Separately, Morgan Stanley upgraded InnoCare Pharma to an “overweight” rating in a report on Thursday. One research analyst has rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy”.

InnoCare Pharma Company Profile

InnoCare Pharma Ltd is a China-based, clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule targeted therapies for oncology. Headquartered in Shenzhen, Guangdong Province, the company leverages structure-based drug design and comprehensive preclinical screening to advance drug candidates that address high-unmet-need cancers.

The company’s development pipeline comprises multiple small-molecule inhibitors in various stages of preclinical and early clinical evaluation.